Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

Steven Huy Han, Milan Kinkhabwala, Paul Martin, Curtis Holt, Natalie Murray, Philip Seu, Steven Rudich, D. Hiserodt, David Imagawa, Ronald W. Busuttil

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.

Original languageEnglish (US)
Pages (from-to)2245-2247
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume93
Issue number11
DOIs
Publication statusPublished - Nov 1 1998
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this